Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer

Chang, Mei Chi; You, San–Lin; Chen, Chien Jen; Liu, Chun‐Jen; Lai, Ming‐Wei; Wu, Tai‐Hsi; Wu, Shu Fen; Lee, Chuan Mo; Yang, Shih-Chieh; Chu, Hsueh-Liang; Wang, Tsang Eng; Chen, Bor Wen; Chuang, Wan‐Long; Soon, Maw–Soan; Lin, Ching Yih; Chiou, Shu Ti; Kuo, Hsu Sung; Chen, Ding‐Shinn; Yang, Yao; Lo, Gin Ho; Kong, Man San; Wang, Po Ming; Yang, Ching-Ping; Chu, Chia Hsiang; Lin, Lung Huan; Chien, Rong Nan; Lee, Tzong Hsi; Yang, Kuo Ching; Liao, Li Ying; Mo, Lein‐Ray; Liu, Jean Dean; Yang, Tzeng Huey; Lo, Ching Chu; Tsai, Ming Hung; Chou, Chang Hua; Cheng, Yi‐Chiao

doi:10.1053/j.gastro.2016.05.048

Cited by 205 publications

(150 citation statements)

References 23 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…An effective strategy shown to decrease the incidence of HCC is vaccination against HBV. A recent analysis of two Taiwanese HCC registries of 1,509 patients diagnosed with HCC from 1983-2011 demonstrated an incidence per 10 5 person-years of 0.92 in the unvaccinated cohort and 0.23 in the vaccinated cohort [2] . Another appealing strategy to decrease the incidence of HCC in patients with chronic hepatitis B is inhibition of viral replication.…”

Section: H Epatitis B Vir Us (H Bv ) Is a D N A Vir Us That Incorporamentioning

confidence: 99%

The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

Ayoub¹,

Dailey²,

Martin³

et al. 2017

View full text Add to dashboard Cite

How to cite this article: Ayoub WS, Dailey F, Martin P, Jones PD. The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings. Hepatoma Res 2017;3:302-8.Worldwide, hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality. In men, it is the fifth most common cancer and seventh most common in women; HCC is the second highest cause of cancer-related death worldwide. It is less prevalent in the USA and Northern Europe and more prevalent in Eastern and South-Eastern Asia. Over 700,000 cases are diagnosed each year -half of which occur in China -and result in roughly the same number of deaths per year. HCC significantly impairs quality of life and is associated with great costs to society. It is estimated that half of the deaths from HCC are associated with hepatitis B virus (HBV). Fortunately, HBV vaccination and antiviral therapy have shown excellent efficacy in decreasing the incidence of HCC. We will discuss the relationship of HBV to HCC, address available treatments for HBV and the impact of treatment on the development of HCC. Key words:Liver cancer, hepatocellular carcinoma, hepatitis B, nucleos(t)ides, entecavir; tenofovir, lamivudine ABSTRACTArticle history:

show abstract

Section: H Epatitis B Vir Us (H Bv ) Is a D N A Vir Us That Incorporamentioning

confidence: 99%

The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

Ayoub¹,

Dailey²,

Martin³

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, due to the global utilization of vaccination programs the HBV-associated HCC incidences are getting lower. [3] One-third of the cirrhotic population develops an HCC throughout their lives, with an annual incidence of 3-5%. [3] "PERISH" fl owchart for selection of the patients with resectable "PERISH" fl owchart for selection of the patients with resectable hepatocellular carcinoma hepatocellular carcinoma Cuneyt Kayaalp, H. Kerem Tolan, Mehmet Caglikulekci Liver Transplantation Institute, Inonu University, 44315 Malatya, Turkey This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.…”

Section: Introductionmentioning

confidence: 99%

“…However, due to the global utilization of vaccination programs the HBV-associated HCC incidences are getting lower. [3] One-third of the cirrhotic population develops an HCC throughout their lives, with an annual incidence of 3-5%. [3] TREATMENT DECISION There are numerous classifications and staging systems for planning the treatment of HCCs, but every HCC and every patient must be evaluated individually.…”

Section: Introductionmentioning

confidence: 99%

“…[3] One-third of the cirrhotic population develops an HCC throughout their lives, with an annual incidence of 3-5%. [3] TREATMENT DECISION There are numerous classifications and staging systems for planning the treatment of HCCs, but every HCC and every patient must be evaluated individually. Treatment options for HCC have a wide range of modalities that change according to the stage of the tumor and the patient specific factors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

“PERISH” flowchart for selection of the patients with resectable hepatocellular carcinoma

Kayaalp¹,

Tolan²,

Caglikulekci³

2015

Hepatoma Res

View full text Add to dashboard Cite

A selection of patients with hepatocellular carcinoma (HCC) for surgical resection is crucial and algorithms/staging systems help surgeons to decide on a standard treatment for each patient and each HCC stage. However, there are always diffi culties in remembering and/or recalling the contents of the algorithms/staging systems. Moreover, most algorithms/staging systems do not include data about the extent of hepatectomy, intra-hepatic distribution of tumor(s), and technical feasibility of resection, all of which are vital in the surgeons' decision-making process. Here, we aimed to present a simple and handy mnemonic acronym for selecting resectable HCCs in surgical practice. This was reproduced from the existing well-known staging systems. The designed mnemonic acronym is a phrase "PERISH" and it includes asking for Performance of patient, Extra-hepatic disease, Reserve of the liver, Intra-hepatic distribution, Stratifying risk factors, and Hepatectomy size in order. Performance based on whether the patient is mostly bedridden or not should be the fi rst step of evaluation. Next, asking for suspicious metastasis as bone pain and radiological evaluation of abdomen/thorax is mandatory. The calculation of Child-Pugh score is only the third step. Good candidates for surgical resection should be Child-Pugh "A" with normal bilirubin levels. Technical feasibility of resection, according to the intra-hepatic distribution of tumor(s) should be done later, and the candidates preferably should not have portal hypertension (no splenomegaly, no thrombocytopenia). If the patient fulfi lls all the previous steps, the surgeon may perform indo-cyanine green clearance test. Consequently, following the PERISH fl owchart may prevent "perish" of the surgeons while selecting the appropriate resectable HCCs.Key words: Hepatectomy; hepatocellular carcinoma; surgery; surgical education INTRODUCTION Hepatocellular carcinoma (HCC) is the primary malignancy of the hepatocytes accounting for nearly 90% of all the liver cancers, which is the fifth most common cancer around the world.[1] HCCs are most common in damaged liver parenchyma. Chronic hepatitis B virus (HBV) and hepatitis C virus, alcohol and steatohepatitis-induced hepatocyte damage are the most common predisposing etiological factors for HCCs.[2] HBV is the main etiology responsible for most of the HCC cases observed in Africa and the Asian parts of the world due to its high prevalence. However, due to the global utilization of vaccination programs the HBV-associated HCC incidences are getting lower. [3] One-third of the cirrhotic population develops an HCC throughout their lives, with an annual incidence of 3-5%. [3] "PERISH" fl owchart for selection of the patients with resectable "PERISH" fl owchart for selection of the patients with resectable hepatocellular carcinoma hepatocellular carcinoma Cuneyt Kayaalp, H. Kerem Tolan, Mehmet Caglikulekci Liver Transplantation Institute, Inonu University, 44315 Malatya, Turkey This is an open access article distributed under th...

show abstract

“…7 According to a Taiwan study, the immunoprophylaxis method is an important factor for hepatocellular carcinoma development. 9 Therefore, the immunoprophylaxis method and quality of immunoprophylaxis would be important risk factors in the failure of MTCT prevention.…”

mentioning

confidence: 99%

Letter: role of tenofovir to prevent mother‐to‐child transmission of hepatitis B virus—authors’ reply

Lee

Hyun

Kim

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer

Abstract: Based on an analysis of 1509 patients with HCC in Taiwan, immunization of infants against HBV reduces their risk of developing HCC as children and young adults. Improving HBV vaccination strategies and overcoming risk factors could reduce the incidence of liver cancer.

Cited by 205 publications

References 23 publications

The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

“PERISH” flowchart for selection of the patients with resectable hepatocellular carcinoma

Letter: role of tenofovir to prevent mother‐to‐child transmission of hepatitis B virus—authors’ reply

Contact Info

Product

Resources

About